• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Alpha Tau Medical (DRTS) Looks Pricey After Early Alpha DaRT Trial Results

    Simply Wall St·09/29/2026 15:13:50
    语音播报

    Why Alpha Tau Medical Is Back on Investor Radars

    Alpha Tau Medical (NasdaqCM:DRTS) has jumped into focus after early trial updates on its Alpha DaRT cancer therapy showed strong response data in head and neck cancer, glioblastoma, and pancreatic tumors.

    The same update also flagged upcoming readouts in skin, brain, and pancreatic cancer, alongside details on physician demand, regulatory progress, and the company’s cash and manufacturing footprint.

    Against that clinical backdrop, Alpha Tau Medical’s share price has moved to US$15.04, with a 90-day share price return of 19.55% and a year-to-date share price gain of 211.39%. This has contributed to a 1-year total shareholder return of 253.88% that points to powerful momentum rather than a short-lived reaction to the latest trial headlines.

    Spot emerging oncology stories moving on real trial data by scanning our curated list of 37 healthcare AI stocks that, like Alpha Tau Medical, link new treatment approaches with advanced medical technology.

    After a 1 year total return above 250% and fresh trial buzz, the real tension for Alpha Tau Medical now is simple. Does paying US$15.04 today make more sense than waiting for a cheaper shot at the story?

    Price To Book Of 31.5x For Alpha Tau Medical: Is It Justified?

    On any basic yardstick, Alpha Tau Medical looks expensive. The stock trades at $15.04, and the latest checks put its P/B ratio at 31.5x, far above both its peers and the wider US Medical Equipment group.

    P/B compares a company’s market value to its net assets on the balance sheet. For a clinical stage oncology business with effectively no revenue and a reported net loss of $92.574m, most of that value reflects what investors think Alpha Tau Medical’s Alpha DaRT platform could become rather than what currently shows up in accounting equity.

    That gap is large. The peer group average P/B multiple is 2x, while the broader US Medical Equipment industry sits at 2.6x. Against those reference points, a 31.5x reading suggests the market is paying a very rich premium for Alpha Tau Medical relative to both direct comparables and the sector as a whole.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 31.5x (OVERVALUED)

    Still, the story around Alpha Tau Medical can change quickly if Alpha DaRT trial results disappoint or if fresh capital is needed to fund ongoing losses.

    Find out about the key risks to this Alpha Tau Medical narrative.

    Next Steps

    Mixed signals around Alpha Tau Medical’s valuation and trial progress can pull you in both directions, so act early and stress test the story against independent checks using the 1 key reward and 3 important warning signs.

    Looking For More Ideas Beyond Alpha Tau Medical?

    If Alpha Tau Medical has your attention, do not stop your research here. Broaden your watchlist with a few focused screeners that surface very different types of opportunities.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.